Biological
anti-CD19 CAR-NK cells
anti-CD19 CAR-NK cells is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
unknown1
Enrolling by invitation1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
unknown133%
enrolling_by_invitation133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
enrolling_by_invitationphase_1
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
NCT06827782
recruitingphase_1
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus
NCT06421701
unknownphase_1
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
NCT02892695
Clinical Trials (3)
Showing 3 of 3 trials
NCT06827782Phase 1
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
NCT06421701Phase 1
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus
NCT02892695Phase 1
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3